CTOs on the Move

deCODE genetics

www.decode.com

 
deCODE genetics is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.decode.com
  • 1000 Winter St Ste 3100
    Waltham, MA USA '02451
  • Phone: 354.570.1900

Executives

Name Title Contact Details

Similar Companies

Lexaria Bioscience

Lexaria Bioscience Corp. has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds. Lexaria has multiple patents pending and granted in over 40 countries around the world and was granted its first patent in the USA in October, 2016. Lexaria`s technology provides increases of up to 10x in intestinal absorption rates; more rapid delivery to the bloodstream with effects often within 15-20 minutes; and important taste-masking benefits, for orally administered bioactive molecules including but not limited to cannabinoids, vitamins, NSAIDs, and nicotine.

Interpace Biosciences

Interpace Biosciences is a company that provides molecular and related first line diagnostic tests for evaluating risk of cancer, as well as specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted...

Greater Washington Maternal-Fetal Medicine and Genetics

Greater Washington Maternal-Fetal Medicine and Genetics is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regen BioPharma

The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.

VitaKey

VitaKey`s technology platform provides for a wide range of advanced encapsulations triggered by desired pH levels or other stimuli. Our technology delivers targeted and time-controlled release of micronutrients, vitamins, probiotics, nutraceuticals, antioxidants, proteins and amino acids, and flavors, as well as excellent bioavailability.